Inhibition of Osteoclast Differentiation and Promotion of Osteogenic Formation by Wolfiporia extensa Mycelium
Journal of Microbiology and Biotechnology · 2023
DOI: 10.4014/jmb.2304.04048 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Microbiology and Biotechnology, 2023. Verfasst von Tae Hyun Son und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea. Hauptthemen laut MEDLINE: Wolfiporia, Osteoporosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Forest Science.
Abstract (Originalsprache)
Osteoporosis, Greek for "porous bone," is a bone disease characterized by a decrease in bone strength, microarchitectural changes in the bone tissues, and an increased risk of fracture. An imbalance of bone resorption and bone formation may lead to chronic metabolic diseases such as osteoporosis. Wolfiporia extensa, known as "Bokryung" in Korea, is a fungus belonging to the family Polyporaceae and has been used as a therapeutic food against various diseases. Medicinal mushrooms, mycelium and fungi, possess approximately 130 medicinal functions, including antitumor, immunomodulating, antibacterial, hepatoprotective, and antidiabetic effects, and are therefore used to improve human health. In this study, we used osteoclast and osteoblast cell cultures treated with Wolfiporia extensa mycelium water extract (WEMWE) and investigated the effect of the fungus on bone homeostasis. Subsequently, we assessed its capacity to modulate both osteoblast and osteoclast differentiation by performing osteogenic and anti-osteoclastogenic activity assays. We observed that WEMWE increased BMP-2-stimulated osteogenesis by inducing Smad-Runx2 signal pathway axis. In addition, we found that WEMWE decreased RANKL-induced osteoclastogenesis by blocking c-Fos/NFATc1 via the inhibition of ERK and JNK phosphorylation. Our results show that WEMWE can prevent and treat bone metabolic diseases, including osteoporosis, by a biphasic activity that sustains bone homeostasis. Therefore, we suggest that WEMWE can be used as a preventive and therapeutic drug.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea.
- Forest Biomaterials Research Center, National Institute of Forest Science (NIFoS), Jinju 52817, Republic of Korea.
- Forest Microbiology Division, Department of Forest Bio-Resources, NIFoS, Suwon 16631, Republic of Korea.
Förderung
- National Institute of Forest Science
Zitieren
APA
Son, T. H., Kim, S. H., Shin, H. L., Kim, D., Huh, J. S., Ryoo, R., Choi, Y., & Choi, S. W. (2023). Inhibition of Osteoclast Differentiation and Promotion of Osteogenic Formation by Wolfiporia extensa Mycelium. Journal of Microbiology and Biotechnology. https://doi.org/10.4014/jmb.2304.04048
Vancouver
Son TH, Kim SH, Shin HL, Kim D, Huh JS, Ryoo R, et al. Inhibition of Osteoclast Differentiation and Promotion of Osteogenic Formation by Wolfiporia extensa Mycelium. Journal of Microbiology and Biotechnology. 2023. doi:10.4014/jmb.2304.04048
BibTeX
@article{Son2023,
author = {Son, Tae Hyun and Kim, Shin-Hye and Shin, Hye-Lim and Kim, Dongsoo and Huh, Jin-Sung and Ryoo, Rhim and Choi, Yongseok and Choi, Sik-Won},
title = {Inhibition of Osteoclast Differentiation and Promotion of Osteogenic Formation by Wolfiporia extensa Mycelium},
journal = {Journal of Microbiology and Biotechnology},
year = {2023},
doi = {10.4014/jmb.2304.04048}
}
EUVIMED